FDA says Novartis' Prexige 'not approvable'

Share this article:

Novartis said it has received a "not approvable" letter from the FDA for its COX-2 inhibitor Prexige (lumiracoxib) as an arthritis treatment.

The drugmaker said plans to continue discussions with FDA and believes Prexige  is “a valuable treatment option for appropriate patients with osteoarthritic pain.”

Novartis had touted Prexige as a potential blockbuster, with hopes for sales of over $1 billion a year, but CEO Daniel Vasella said earlier this month that the drug was a long shot to gain US approval after Australian regulators decided to withdraw it from the market in early 2007 due to safety concerns.

Recent setbacks for Novartis mean the company doesn't expect to return to double-digit sales growth until the second half of 2008, Vasella told investors last month.

“We had a significant number of disappointments,” Vasella said in a published report. We “will have a much less dynamic year in the pharma business in the second half (than in the first), which will affect the group as a whole.”

Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...